It is the second major deal of this kind in the space of year for Abzena.
Showing 25 of 1555
“Funds raised in November provide capital to take the company towards profitability and we continue to invest in the pipeline, manufacturing and commercial platforms,” CEO JIm Phillips.
The potential value of the deal cited above consists of licence fees and milestone payments. In addition, Abzena would receive a royalty on sales of approved drugs incorporating its technology.
It completed its long-mooted listing on Nasdaq where, some would argue, pharmaceutical companies (and how to value them) are better understood.
Turnover was £40.4mln in the six months to December
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off
Income from probes (used in patients in surgery or recovery) rose 4% over the year
The ‘pivotal’ study will now look at overall survival rather than just progression-free survival
Revenues in 2016 were £38mln, up 26%, with an order backlog at the end of the year of £70mln.
That at least is the opinion of the respected pharma team at Jefferies, which raised its valuation of shares Europe’s largest drugs firm.
“[We are] entering a very exciting phase, which should result in the crystallisation of substantial value,” said chief executive, Dr Satu Vainikka.
The deal is with German group STADA, which owns Huddersfield-based Thornton & Ross.
We look at what looks to be a savvy investment by the UK biotech.
Sareum is entitled to 27.5% of all payments arising from the Chk1 licence agreement
A new study has found that the kind of bacteria you have in your gut will impact your attempts to lose weight
Concepta wants to launch myLotus into the £350mln UK and Europe market in the second half of this year
Arrowhead Pharmaceuticals is working in the same space as its UK contemporary – gene silencing – and is aiming to provide a new way of tackling difficult-to-treat diseases such as cancer.
Initiating coverage of the vaccines business, finnCap set a price target of 40p a share based on its analysis of the company’s peer group.
The condoms will be marketed under the brand name Futura Max Manex Super.
The study showed the response to SCIB1 was “significantly stronger” at higher doses, while the drug worked better for those patients who already had the tumour removed before treatment.
Consort said Nivocations is terminating the deals with its Bespak Europe unit with immediate effect due to lack of a commercial launch of Voke before December 31.
The risk profile may have moved up a notch or two but Beaufort Securities believes the potential for "bonanza returns" in the next 12 months is there
J&J abruptly bowed out of the bid process for Actelion last week after the Swiss firm said that it was “engaged in discussions with another party”.
It has delivered on its plan to have 200 sufferers of the life-threatening auto-immune disease taking part in the study by the end of the year.
The AIM-listed life sciences group is teaming up with Washington University in St Louis and will used the AIM-listed firm’s cell engineering platform, CARMA, to develop immunotherapy drug candidates.